Management of the overdose of paliperidone 3-monthly injection: A case report

被引：0
|
作者：
Jin, Fei Xue [1 ]
Malik, Asad [2 ]
机构：
[1] Northern Sydney Local Hlth Dist, Sydney, NSW, Australia
[2] Napean Blue Mt Older Persons Mental Hlth Serv, Kingswood, NSW, Australia
来源：
AUSTRALASIAN PSYCHIATRY | 2023年 / 31卷 / 03期
关键词：
D O I：
10.1177/10398562231162233
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：405 / 405
页数：1
相关论文
共 50 条
  • [41] Factors predicting relapse and treatment discontinuation with paliperidone 3-monthly long-acting injection: A 2-year naturalistic follow-up study
    Clark, Ivana
    Wallman, Phoebe
    Cornelius, Victoria
    Taylor, David
    EUROPEAN PSYCHIATRY, 2021, 64 (01)
  • [42] Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
    Mathews, Maju
    Nuamah, Isaac
    Savitz, Adam J.
    Hough, David W.
    Najarian, Dean
    Kim, Edward
    Gopal, Srihari
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 2807 - 2816
  • [43] A PRELIMINARY COST ANALYSIS OF SCHIZOPHRENIC PATIENTS STABILIZED ON 1-MONTHLY LONG ACTING PALIPERIDONE PALMITATE (PP1M) INJECTION SWITCHING TO PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION (PP3M) IN THE PUBLIC SECTOR OF HONG KONG
    Choon, W. Y.
    Wu, D. B.
    Lee, K. K.
    VALUE IN HEALTH, 2017, 20 (09) : A711 - A711
  • [44] Death following an intramuscular injection of paliperidone: A case report
    Drevin, Guillaume
    Ripault, Bruno
    Ballot-Ragaru, Jean-Baptiste
    Bonnot, Estelle
    Palayer, Maeva
    Gaconnet, Alexia
    Deguigne, Marie
    Dubourg, Olivier
    Malbranque, Stephane
    Jousset, Nathalie
    Lelievre, Benedicte
    TOXICOLOGIE ANALYTIQUE ET CLINIQUE, 2020, 32 (02) : 132 - 136
  • [45] PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA: BASELINE INTERIM ANALYSIS OF A NATURALISTIC, 52-WEEK, PROSPECTIVE STUDY
    Hargarter, L.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    Peters, K.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 143 - 144
  • [46] Clinical effectiveness of paliperidone palmitate 3-monthly and 1-monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database
    Chiang, Chih-Lin
    Chinen, Madoka
    Daskiran, Mehmet
    Wakamatsu, Akihide
    Turkoz, Ibrahim
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2024, 44 (04) : 716 - 727
  • [47] COST CONSEQUENCE OF INTRODUCING PALIPERIDONE PALMITATE 3-MONTHLY FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN THE ENGLISH NATIONAL HEALTH SERVICE (NHS)
    Ming, T.
    Rao, B.
    Bird, A.
    VALUE IN HEALTH, 2017, 20 (09) : A710 - A711
  • [48] Paliperidone palmitate 3-monthly formulation in schizophrenia - baseline interim analysis of a naturalistic, 52-week, prospective study
    Hargarter, L.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S950 - S950
  • [49] Once-monthly paliperidone injection for the treatment of schizophrenia
    Bishara, Delia
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 561 - 572
  • [50] Paliperidone palmitate 3-monthly formulation in schizophrenia - baseline interim analysis of a naturalistic, 52-week, prospective study
    Hargarter, L.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    EUROPEAN PSYCHIATRY, 2018, 48 : S107 - S108
12345